

Italy
Marcela Luque
Phone: 0039 344 340 8704
Email: marcela.luque@springernature.com

AIFA - Agenzia Italiana del Farmaco
Sra. Annarita Sapienza
Subject: Proposal Q-43026
Offer valid to: May 31, 2023

June 3, 2022,

Dear Ms. Sapienza,

Thank you for considering Springer Nature research to support your research needs. We are committed to meeting your requirements and providing a seamless experience through our platforms:

- **SpringerLink** provides access to our collection of online Journals and eBooks. The SpringerLink platform covers the full range of disciplines in Science, Technology, and Medicine, as well as the Humanities and Social Sciences.
- **Nature.com** provides access to all Nature Research publications and services, including news and comment from Nature, the #1 weekly interdisciplinary science journal. You will also find our Academic and Reviews journals on the Nature.com platform
- **AdisInsight** is an integrated and easy-to-use drug development database providing scientifically-based content compiled from multiple sources to provide access to relevant, unbiased records with clear referencing and links to original source across publishers.

The proposal below includes details and pricing for the products we have discussed, as well as a License Agreement for signature.

We are committed to supporting your implementation and promotion of Springer Nature resources. Following your purchase, you will be introduced to your dedicated Account Development Manager. Onboarding resources are available for both Admins and End Users at your institutions. Training sessions can also be arranged at your request.

Please let me know if you have any questions. I look forward to discussing this proposal in more detail.

Sincerely,
Marcela Luque

The below products are part of your proposal.

AdisInsight

AdisInsight helps users to stay at the forefront of research by providing the most compelling current evidence on drug treatments being developed worldwide – how well they work, how safe they are, who is working on them, and how soon they will be available.

The user-friendly database provides easy access to expertly-written drug information, with a single search equivalent to searching across thousands of journals, conference proceedings, company websites and other published sources.

SPRINGER NATURE

Key Facts

- A database for drug research and development, disease treatment and decision making, based on trusted, scientifically sound data
- Expertly reviewed, assessed and summarized by a team of scientists
- A single search delivers results on drugs, trials, deals and safety
- Now including curated biomarker data in drug and trial profiles

LICENSE AGREEMENT

LICENSE DETAILS

Quote ID: Q-43026

Customer: AIFA - Agenzia Italiana del Farmaco

Primary Address: Via del Tritone 181, 187 ROMA, Italy

This License Agreement between Springer Nature Customer Service Center GmbH, Tiergartenstrasse 15-17, 69121 Heidelberg, Germany ("Licensor") and Customer incorporates the following documents:

- This License Details page including Attachment 1: Customer and Licensee Information;
- The Product Terms;
- The General Terms and Conditions incorporated herein by reference and located at

www.springernature.com/legal/ROW_Corporate_Terms_and_Conditions_5.0_sni

When executed by both parties, this License Agreement shall be deemed effective on the earlier of (i) the earliest Commencement Date for any Product licensed hereunder, or (ii) the last date of signature by Licensor or Customer.

AIFA - Agenzia Italiana del Farmaco - Springer Nature collaboration

Offer valid to: September 30, 2022

Quote Table (Q-43026)

Start Date: June 01, 2022 End Date: May 31, 2023

Product Family	Product Terms ¹	Access Type ²	List Price ³	Discount (%)	Customer Price ³ (License Fee)
AdisInsight	O		€5,029.44		€5,029.44
Total			€5,029.44		€5,029.44

1. Label of the applicable Product Terms

2. Indication for access type: CA = Continuing Access, AO = Access Only. However, the specific access rights are detailed in, and governed by the Product Terms relevant for the Product Family.

3. Prices do not include taxes.




CERTAIN CONTENT MADE AVAILABLE TO LICENSEE MAY BE SUBJECT TO AND LICENSED UNDER OPEN ACCESS LICENSE TERMS ("OPEN ACCESS CONTENT"). OPEN ACCESS CONTENT IS SOLELY SUBJECT TO THE APPLICABLE OPEN ACCESS LICENSE TERMS, SPECIFIED WITHIN THE CONTENT. FOR THE AVOIDANCE OF DOUBT, PAYMENT OF LICENSE FEES IS NOT RELATED TO THE ACCESS OR USE RIGHTS WITH RESPECT TO OPEN ACCESS CONTENT

1 Payment Terms

SPRINGER NATURE

1.1 The License Fee(s) is/are due within 60 days from the date of invoice.

IN WITNESS WHEREOF, the parties have signed this License Agreement by their respective, duly authorized representatives on the date set forth below

CUSTOMER	LICENSOR
Signature:	Signature:
	
Name: Jelena Ivanovich	Name: Peter Kaul
Title: AIFA contact individual	Title: Director Global Logistics
Date: 	Date: June 3, 2022

Attachment 1

Customer and Licensee Information

Customer Information:

- Legal Entity Name: AIFA - Agenzia Italiana del Farmaco
- Address: Via del Tritone 181, 187 ROMA, Italy
- Contact Individual: Jelena Ivanovich, j.ivanovic@aifa.gov.it
- VAT / GST / Indirect Tax Reg. No.: IT08703841000
- Business Partner ID: 3003808089

Customer is Licensee for all purposes under the License Agreement.

Customer will supply Licensor with an initial list of its IP addresses used for the access to the Content (if not already supplied to Licensor), prior to the Commencement Date and shall notify Licensor of any IP address changes. Licensor reserves the right to confirm accuracy of the IP address(es) supplied before grant of access. Notwithstanding anything to the contrary in this License Agreement, notifications of IP address changes may be made in electronic format. Licensor's obligation to timely provide access to the Content under this License Agreement is conditioned on Licensee's provision of its IP addresses.

Customer represents that neither Customer nor any Licensee Affiliate is currently the subject or target of any sanctions imposed by the sanctions authority of any government and agrees that it will not supply Licensor with any IP Address that may provide access to the Content to any entity or person when providing such access would violate applicable sanctions. Licensor may unilaterally terminate this License Agreement with immediate effect on written notice if Licensor has reasonable grounds to believe that either (i) Customer is in breach of that representation or (ii) Licensor may violate applicable sanctions by the provision of access to Content under the License Agreement due to a change in law or the placement of an entity or person on a sanctions black list

Product Terms (O)
AdisInsight

1. Term

The Term shall begin on June 01, 2022 (the "Commencement Date") and shall end on May 31, 2023.

2. Reports

Standard rights: In addition to the rights granted to Licensee in the General Terms and Conditions, Licensor hereby grants Licensee the non-exclusive, non-sublicensable and non-transferable right to create reports which may include individual items from the selected Modules solely for Licensee's own internal purpose in connection with its own business, and not in connection with providing such reports or any data or service to any third party. Such reports may be in print or electronic format.

3. Content

3.1 AdisInsight

Notwithstanding anything to the contrary in the General Terms and Conditions, Authorized Users are limited to the number of Authorized Users of Licensee indicated below

Database	Module(s)	Number of Authorized Users
AdisInsight	Drugs & Deals	5
	Trials	5